Clinical Trials Logo

Hidradenitis clinical trials

View clinical trials related to Hidradenitis.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06374212 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Anifrolumab for Hidradenitis Suppurativa

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This clinical trial aims to study if a drug called anifrolumab works to treat Hidradenitis Suppurativa (HS) as well as its effect in quality of life before and after treatment. Anifrolumab is a monoclonal antibody that inhibits several processes that have been shown to be involved in the development of HS. The study lasts approximately 40 weeks separated into a screening, treatment, and follow-up phase. Researchers determine if it is safe for the you to receive the drug and if you are eligible for the study during Screening. If eligible for the study, the treatment phase lasts 24 weeks (or six months) with one follow-up visit 12 weeks after the last visit in the treatment phase. During the treatment phase, participants will be asked to come to clinic every two weeks for the first month of treatment, and monthly thereafter for a total of eight treatment visits. Participants will be asked to: - Complete questionnaires asking about the effect of HS in their daily lives and their perception of HS and treatment received. - Receive related medical evaluation - Receive the study drug intravenously - Stay 20 minutes after the infusion for monitoring

NCT ID: NCT06370052 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Pathophysiological Basis of Hidradenitis Suppurativa

Start date: May 1, 2024
Phase:
Study type: Observational

HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous glands and surrounding tissue. Because of its frequent recurrence and chronicity, it represents a major public health problem and there is a need for better diagnosis and new and more effective drugs. This research can be a part of realizing the stated needs.

NCT ID: NCT06326476 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

A Study to Demonstrate the Safety and Efficacy of Siplizumab in the Treatment of Hidradenitis Suppurativa

Start date: January 2025
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.

NCT ID: NCT06324695 Not yet recruiting - Psoriasis Clinical Trials

Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases

DEVISE
Start date: March 2024
Phase: N/A
Study type: Interventional

This project aims to develop and evaluate an online intervention to prevent and/or reduce self-stigma in German patients with visible chronic skin diseases. Evaluation of the intervention with regard to effectiveness and feasibility will follow an open-label randomized controlled design with 550 patients in total. The results of the program are expected to provide new insights and markedly extended knowledge on the mechanisms of self-stigma in chronic skin conditions. The new online intervention can be used in routine care, aiming for better patient care in practice and, ultimately decreased extent of self-stigma, increased quality of life of patients, and decreased rates of depression, anxiety, and suicide ideation.

NCT ID: NCT06301256 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa

Start date: March 11, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the clinical efficacy and safety of tirzepatide in subjects with moderate to severe hidradenitis suppurativa. The study will be conducted over 24 weeks on active therapy followed by a eight-week observational follow-up visit. The total length of the study will be 32 weeks .

NCT ID: NCT06237465 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Botulinum Toxin-A for Hidradenitis Suppurativa

Start date: April 2024
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to determine if the medication Botulinum Toxin-A (BTX-A) is effective in treating hidradenitis suppurativa (HS)

NCT ID: NCT06201858 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa

Start date: January 2025
Phase:
Study type: Observational

This study aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in hidradenitis suppurativa clinical trials. Understanding these factors will significantly improve the relevance and effectiveness of future research endeavors. Ultimately, this trial endeavors to deepen our understanding of the factors impacting hidradenitis suppurativa clinical trial participation. Enhancing participation rates could accelerate the development of innovative treatments for this debilitating condition.

NCT ID: NCT06082323 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Phase 1 Study of LT-002-158 Intended for the Treatment of Skind Disorder in Healthy Adult Volunteers

Start date: January 10, 2024
Phase: Phase 1
Study type: Interventional

LT-002-158 is a novel small molecule drug being developed as a potential therapy for the treatment of skin disorder disease includes Hidradenitis Suppurativa and Atopic Dermatitis.

NCT ID: NCT05821478 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients

ABCESS2
Start date: April 15, 2024
Phase: Phase 3
Study type: Interventional

The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative

NCT ID: NCT05762484 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa, Acne Inversa

Efficacy of Laser Hair Removal Therapy in HS

HaLa
Start date: April 2023
Phase: N/A
Study type: Interventional

Hidradenitis suppurativa (HS) is a chronic, recurrent and debilitating inflammatory skin disorder, characterized by painful inflamed nodules, abscesses and tunnels in the skin folds such as the axilla, inguinal region and gluteal area. The primary event in HS is occlusion of the hair follicle. HS is a notoriously difficult to treat disease, because treatment options are limited and evidence based treatments are scarce. Prevention of diseases is an important topic in medicine. However, current clinical trials in HS are focusing on anti-inflammatory drugs in patients with severe HS, whereas prevention and treatment of patients with more common mild HS is neglected. Laser hair removal therapy is a non-invasive procedure with minimal treatment discomfort for patients. Previous limited studies have suggested positive results in favor of laser hair removal therapy in HS. We therefore hypothesize that hair depilation using laser hair removal therapy may prevent the formation of new lesions and flares of the disease. The objective is to assess the efficacy of laser hair removal therapy in patients with mild to moderate HS.